166 related articles for article (PubMed ID: 18094422)
1. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
van Erp NP; Gelderblom H; Karlsson MO; Li J; Zhao M; Ouwerkerk J; Nortier JW; Guchelaar HJ; Baker SD; Sparreboom A
Clin Cancer Res; 2007 Dec; 13(24):7394-400. PubMed ID: 18094422
[TBL] [Abstract][Full Text] [Related]
2. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
Connolly RM; Rudek MA; Garrett-Mayer E; Jeter SC; Donehower MG; Wright LA; Zhao M; Fetting JH; Emens LA; Stearns V; Davidson NE; Baker SD; Wolff AC
Breast Cancer Res Treat; 2011 May; 127(1):153-62. PubMed ID: 21350820
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of imatinib.
Peng B; Lloyd P; Schran H
Clin Pharmacokinet; 2005; 44(9):879-94. PubMed ID: 16122278
[TBL] [Abstract][Full Text] [Related]
7. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Br J Pharmacol; 2012 Apr; 165(8):2787-98. PubMed ID: 22014153
[TBL] [Abstract][Full Text] [Related]
8. Effect of St John's wort on imatinib mesylate pharmacokinetics.
Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
10. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
11. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
[TBL] [Abstract][Full Text] [Related]
14. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
[TBL] [Abstract][Full Text] [Related]
15. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
16. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Gardner ER; Burger H; van Schaik RH; van Oosterom AT; de Bruijn EA; Guetens G; Prenen H; de Jong FA; Baker SD; Bates SE; Figg WD; Verweij J; Sparreboom A; Nooter K
Clin Pharmacol Ther; 2006 Aug; 80(2):192-201. PubMed ID: 16890580
[TBL] [Abstract][Full Text] [Related]
17. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
Kasserra C; Sansone-Parsons A; Keung A; Tetteh E; Assaf M; O'Mara E; Marbury T
Clin Pharmacokinet; 2010 Jun; 49(6):397-406. PubMed ID: 20481650
[TBL] [Abstract][Full Text] [Related]
18. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
20. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]